Synovial sarcoma accounts for nearly 10% of all soft tissue tumors. With 800-1000 individuals undergoing a diagnosis for the condition each year, it has an incidence rate of 0.177 per 100,000 people in the United States. As a result, several healthcare and pharmaceutical companies are involved in developing effective synovial sarcoma therapeutics to treat and manage the disease efficiently.
The Synovial Sarcoma Drug Pipeline Report by Expert Market Research gives comprehensive insights into synovial sarcoma therapeutic drugs currently undergoing clinical trials for synovial sarcoma treatment. It covers various aspects related to the details of each of these drugs under development. The synovial sarcoma report assessment includes an analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on synovial sarcoma.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing synovial sarcoma pipeline development activities are covered in the report.
Synovial sarcoma is a rare cancer that primarily affects muscles or ligaments, including arms, legs, knees or feet. The symptoms for this condition may vary based on tumor location or form. It is commonly diagnosed through X-ray, CT scan, ultrasound, or biopsy.
In August 2024, the United States FDA approved Adaptimmune's Tecelra (afamitresgene autoleucel) for treating unresectable or metastatic synovial sarcoma. It is a gene therapy for adults who have received prior chemotherapy. The approval was granted on the basis of an open-label clinical trial that involved 44 patients. The overall response rate (ORR) was 43.2%. With synovial sarcoma emerging drugs belonging to various drug classes getting approvals from vital regulatory authorities, the drug pipeline for synovial sarcoma is promising.
This section of the report covers the analysis of synovial sarcoma drug candidates based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s synovial sarcoma therapeutic assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s synovial sarcoma clinical assessment covers 50+ drug analyses based on the route of administration.
The synovial sarcoma report insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials conducted, with over 60 drugs in the pipeline.
The drug class categories covered under synovial sarcoma pipeline analysis include chemotherapy agents, targeted therapies and immunotherapies, among others. Immunotherapy can be further categorised into immune checkpoint inhibitors as well as T-cell therapies. Each drug class has a different mode of action, and it is recommended based on disease prognosis. Chemotherapy drugs work by killing tumor cells while targeted therapy drugs interfere with particular molecular targets and inhibit further cell growth.
The synovial sarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
The EMR report for the synovial sarcoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in synovial sarcoma pipeline landscape:
Sponsored by Eli Lilly and Company, ramucirumab (in combination with chemotherapy) is being investigated to treat recurrent, refractory, or relapsed pediatric synovial sarcoma. As a part of the CAMPFIRE master protocol, the synovial-sarcoma drug candidate is being evaluated in a randomized open-label Phase 1/2 study.
The drug is under evaluation for treating advanced synovial sarcoma or advanced SMARCB1-loss tumors. Sponsored by Foghorn Therapeutics Inc., FHD-609 is administered intravenously twice a week. The Phase 1 study entails around 104 patients, enrolled for dose escalation and expansion.
As a part of an open-label non-randomized, first-in-human Phase 1/2 study, this synovial-sarcoma therapeutic drug is under investigation to treat synovial sarcoma. It is sponsored by C4 Therapeutics Inc. and assesses antitumor activity along with pharmacokinetics and pharmacodynamics.
Developed by OncoTherapy Science, Inc., this anti-frizzled homolog 10 monoclonal antibody, is being evaluated for its safety and pharmacokinetics against relapsed or refractory synovial sarcoma.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Synovial Sarcoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for synovial sarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into synovial sarcoma collaborations, market trends, regulatory environments, and potential growth opportunities.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share